Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(24):2065-2066; doi:10.1093/jnci/91.24.2065
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Forastiere, A. A.
Right arrow Articles by Trotti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forastiere, A. A.
Right arrow Articles by Trotti, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 24, 2065-2066, December 15, 1999
© 1999 Oxford University Press

EDITORIALS

Radiotherapy and Concurrent Chemotherapy: a Strategy That Improves Locoregional Control and Survival in Oropharyngeal Cancer

Arlene A. Forastiere, Andy Trotti

Affiliations of authors: A. A. Forastiere, Department of Oncology, The Johns Hopkins Oncology Center, Baltimore, MD; A. Trotti, Department of Radiation Oncology, H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL.

Correspondence to: Arlene A. Forastiere, M.D., Department of Oncology, The Johns Hopkins Oncology Center, 600 N. Wolfe St., Rm. 128, Baltimore, MD 21287-8936.

In this issue of the Journal, Calais et al. (1), representing the French Groupe d'Oncologie Radiotherapie Tete et Cou (GORTEC), report a multicenter randomized comparison of radiotherapy and concurrent chemotherapy versus radiotherapy alone in patients with oropharyngeal cancer. Their results add to a growing list of trials that demonstrate superior survival and locoregional control with this combined-modality approach. A group of 222 eligible patients with stage III or IV locally advanced squamous cell carcinoma of the oropharynx were randomly assigned to receive standard daily fraction radiotherapy (2 Gy/day; total dose, 70 Gy), administered alone or with a 4-day regimen of carboplatin and 5-fluorouracil (5-FU), starting on days 1, 22, and 43. After a median follow-up of 35 months, 3-year overall survival (51% versus 31%; P = .02), 3-year disease-free survival (42% versus 20%; P = . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. M. Muanza, A. P. Cotrim, M. McAuliffe, A. L. Sowers, B. J. Baum, J. A. Cook, F. Feldchtein, P. Amazeen, C. N. Coleman, and J. B. Mitchell
Evaluation of Radiation-Induced Oral Mucositis by Optical Coherence Tomography
Clin. Cancer Res., July 15, 2005; 11(14): 5121 - 5127.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Forastiere
Is There a New Role for Induction Chemotherapy in the Treatment of Head and Neck Cancer?
J Natl Cancer Inst, November 17, 2004; 96(22): 1647 - 1649.
[Full Text] [PDF]

Home page
 JCOHome page
A. Fortin, C. Couture, R. Doucet, M. Albert, J. Allard, and B. Tetu
Does Histologic Grade Have a Role in the Management of Head and Neck Cancers?
J. Clin. Oncol., November 1, 2001; 19(21): 4107 - 4116.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Kies, D. J. Haraf, F. Rosen, K. Stenson, M. List, B. Brockstein, T. Chung, B. B. Mittal, H. Pelzer, L. Portugal, et al.
Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer
J. Clin. Oncol., April 1, 2001; 19(7): 1961 - 1969.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling
Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer
J. Clin. Oncol., January 15, 2001; 19(2): 535 - 542.
[Abstract] [Full Text] [PDF]